117 related articles for article (PubMed ID: 3803393)
1. Biologically potent analogues of salmon calcitonin which do not contain an N-terminal disulfide-bridged ring structure.
Orlowski RC; Epand RM; Stafford AR
Eur J Biochem; 1987 Jan; 162(2):399-402. PubMed ID: 3803393
[TBL] [Abstract][Full Text] [Related]
2. Deletion sequences of salmon calcitonin that retain the essential biological and conformational features of the intact molecule.
Epand RM; Epand RF; Stafford AR; Orlowski RC
J Med Chem; 1988 Aug; 31(8):1595-8. PubMed ID: 3397998
[TBL] [Abstract][Full Text] [Related]
3. des-Ser2 salmon calcitonin: a biologically potent synthetic analog.
Schwartz KE; Orlowski RC; Marcus R
Endocrinology; 1981 Mar; 108(3):831-5. PubMed ID: 6257497
[TBL] [Abstract][Full Text] [Related]
4. A noncyclical analog of salmon calcitonin (N alpha-propionyl Di-Ala1,7,des-Leu19 sCT) retains full potency without inducing anorexia in rats.
Yates AJ; Gutierrez GE; Garrett IR; Mencel JJ; Nuss GW; Schreiber AB; Mundy GR
Endocrinology; 1990 Jun; 126(6):2845-9. PubMed ID: 2351097
[TBL] [Abstract][Full Text] [Related]
5. Divergent structural requirements exist for calcitonin receptor binding specificity and adenylate cyclase activation.
Houssami S; Findlay DM; Brady CL; Martin TJ; Epand RM; Moore EE; Murayama E; Tamura T; Orlowski RC; Sexton PM
Mol Pharmacol; 1995 Apr; 47(4):798-809. PubMed ID: 7723741
[TBL] [Abstract][Full Text] [Related]
6. Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues.
Taylor JW; Jin QK; Sbacchi M; Wang L; Belfiore P; Garnier M; Kazantzis A; Kapurniotu A; Zaratin PF; Scheideler MA
J Med Chem; 2002 Feb; 45(5):1108-21. PubMed ID: 11855991
[TBL] [Abstract][Full Text] [Related]
7. Structural and conformational requirements for human calcitonin activity: design, synthesis, and study of lactam-bridged analogues.
Kapurniotu A; Taylor JW
J Med Chem; 1995 Mar; 38(5):836-47. PubMed ID: 7877149
[TBL] [Abstract][Full Text] [Related]
8. Analogue separates biological effects of salmon calcitonin on brain and renal cortical membranes.
Twery MJ; Seitz PK; Nickols GA; Cooper CW; Gallagher JP; Orlowski RC
Eur J Pharmacol; 1988 Oct; 155(3):285-92. PubMed ID: 3266153
[TBL] [Abstract][Full Text] [Related]
9. Conformational requirements for activity of salmon calcitonin.
Findlay DM; Michelangeli VP; Martin TJ; Orlowski RC; Seyler JK
Endocrinology; 1985 Sep; 117(3):801-5. PubMed ID: 4017965
[TBL] [Abstract][Full Text] [Related]
10. Renal receptors for calcitonin: coordinate occurrence with calcitonin-activated adenylate cyclase.
Marx SJ; Aurbach GD
Endocrinology; 1975 Aug; 97(2):448-53. PubMed ID: 169126
[TBL] [Abstract][Full Text] [Related]
11. Calcitonin-sensitive adenylate cyclase in rat renal tubular membranes.
Loreau N; Lepreux C; Ardaillou R
Biochem J; 1975 Sep; 150(3):305-14. PubMed ID: 2153
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and characterization of a model peptide having potent calcitonin-like biological activity: implications for calcitonin structure/activity.
Moe GR; Kaiser ET
Biochemistry; 1985 Apr; 24(8):1971-6. PubMed ID: 2990546
[TBL] [Abstract][Full Text] [Related]
13. Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system.
Pozvek G; Hilton JM; Quiza M; Houssami S; Sexton PM
Mol Pharmacol; 1997 Apr; 51(4):658-65. PubMed ID: 9106632
[TBL] [Abstract][Full Text] [Related]
14. Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions.
Uda K; Kobayashi Y; Hisada T; Orlowski RC; Bastian JW; Arnaud CD; Wakabayashi K
Biol Pharm Bull; 1999 Mar; 22(3):244-52. PubMed ID: 10220278
[TBL] [Abstract][Full Text] [Related]
15. Calcitonin gene related peptide stimulates adenylate cyclase activity in rat striated muscle.
Kobayashi H; Hashimoto K; Uchida S; Sakuma J; Takami K; Tohyama M; Izumi F; Yoshida H
Experientia; 1987 Mar; 43(3):314-6. PubMed ID: 3493916
[TBL] [Abstract][Full Text] [Related]
16. Calcitonin gene-related peptide stimulates adenylate cyclase activation via a guanine nucleotide-dependent process in rat liver plasma membranes.
Yamaguchi A; Chiba T; Yamatani T; Inui T; Morishita T; Nakamura A; Kadowaki S; Fukase M; Fujita T
Endocrinology; 1988 Nov; 123(5):2591-6. PubMed ID: 3049052
[TBL] [Abstract][Full Text] [Related]
17. Conformational flexibility and biological activity of salmon calcitonin.
Epand RM; Epand RF; Orlowski RC; Seyler JK; Colescott RL
Biochemistry; 1986 Apr; 25(8):1964-8. PubMed ID: 3707923
[TBL] [Abstract][Full Text] [Related]
18. Biologically active, derivatizable salmon calcitonin analog: design, synthesis, and applications.
D'Santos CS; Nicholson GC; Moseley JM; Evans T; Martin TJ; Kemp BE
Endocrinology; 1988 Sep; 123(3):1483-8. PubMed ID: 2841096
[TBL] [Abstract][Full Text] [Related]
19. Determinants for calcitonin analog interaction with the calcitonin receptor N-terminus and transmembrane-loop regions.
Stroop SD; Nakamuta H; Kuestner RE; Moore EE; Epand RM
Endocrinology; 1996 Nov; 137(11):4752-6. PubMed ID: 8895343
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic evaluation of the calcitonin analogue SB 205614 in models of osteoclastic bone resorption in vitro and in vivo: comparison with salmon calcitonin and elcatonin.
McSheehy PM; Farina C; Airaghi R; Allievi E; Banfi S; Bertolini D; Ferni G; Frattola D; Oneta S; Pinza M
Bone; 1995 Apr; 16(4):435-44. PubMed ID: 7605704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
